[HTML] sciencedirect.com

[HTML][HTML] Baseline symptom score impact on benefits of glycopyrrolate/formoterol metered dose inhaler in COPD

FJ Martinez, LM Fabbri, GT Ferguson, C Orevillo… - Chest, 2017 - Elsevier
Background The clinical severity of COPD is currently categorized by symptom burden and
exacerbation risk. Previous 24-week phase III trials (NCT01854645 and NCT01854658) that …
被引用次数：60 相关文章

Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD.

FJ Martinez, LM Fabbri, GT Ferguson, C Orevillo… - Chest, 2017 - europepmc.org
Background The clinical severity of COPD is currently categorized by symptom burden and
exacerbation risk. Previous 24-week phase III trials (NCT01854645 and NCT01854658) that …
[HTML] chestnet.org

[HTML][HTML] Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD

FJ Martinez, LM Fabbri, GT Ferguson, C Orevillo… - …, 2017 - journal.chestnet.org
Background The clinical severity of COPD is currently categorized by symptom burden and
exacerbation risk. Previous 24-week phase III trials (NCT01854645 and NCT01854658) that …

Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD

FJ Martinez, LM Fabbri, GT Ferguson, C Orevillo… - …, 2017 - pubmed.ncbi.nlm.nih.gov
Background The clinical severity of COPD is currently categorized by symptom burden and
exacerbation risk. Previous 24-week phase III trials (NCT01854645 and NCT01854658) that …